Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
The analyst added that guidance for 1Q closings was also missed at the low and high ends of the range by 9 and 108 homes.
The analyst also thinks some companies have shown disinterest in Palantir’s offerings at recent presentations.
Source: https://investorplace.com/2023/05/pltr-stock-alert-is-palantir-really-worth-just-5/
The analyst believes that CEO Jack Dorsey’s moves to cut expenses are working, suggesting that its gross profits will continue to grow in 2024.
Source: https://investorplace.com/2023/12/why-these-3-cathie-wood-stocks-should-be-on-your-radar-in-2024/
The analyst believes that the stock-based compensation is only partly to blame for the poor share price performance and thinks that shares will likely trade toward the firm’s $40 target price for the stock.
The analyst believes that traders would now start locking in their profits and this may push the coin's price down to the $0.266 level.
The analyst continues to view the risk/reward set-up favorably with EPS likely bottoming in 2022/early 2023, and solid earnings growth potential over the medium to long-term.
The analyst issued a $275 price target and an “outperform” rating on shares.
Source: https://investorplace.com/2023/03/nvda-stock-price-predictions-will-nvidia-win-the-ai-arms-race/
The analyst notes that Docebo is poised to gain share and deliver a balanced mix of growth and profitability in FY24 thanks to a differentiated product suite and growth initiatives fueled by investments in the indirect channel via SI/OEM relationships.
The analyst provides an analysis of the key trends in each sub-segment of the global companion animal health market report, along with forecasts at the global, regional and country level from 2023-2028.
The analyst said that Nvidia currently traded at 26 times sales and 160 times earnings.
The analyst sees more upside than downside risk to TPX’s core business margins in 2024 from commodity cost benefits and operational efficiencies.
The analyst thinks Genpact remains well positioned to drive improved growth NT given the company's steady pace of significant new logo wins above historical levels in 2023.